Skip to main content
Equibles
BEAM logo

BEAM · Beam Therapeutics Inc.

Track BEAM — free

Use BEAM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about BEAM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$29.07 +2.50 (+9.41%) At close · Aug 19
Market Cap
$2.74B
Shares
103.29M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$29.07 Open$28.41 Day$27.64–29.16 52W close$16.01–37.92 Avg vol 30d1.9M Short int23.5M · 22.8% float · 11.3d Short vol63% Last earningsFeb 24, 2026 DataFeb 2020–Aug 2026 Filing10-Q · Aug 4

Up next

Next earnings call
Jun 15, 2027 Est · unconfirmed · in 43 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +3%
above
Price vs 50-day avg −3%
below
RSI (14) 56
neutral
MACD trend Positive
52-week position 60%
mid-range
Momentum
relative strength
Strong
1-month return +9%
trailing
6-month return +1%
trailing
YTD return +5%
this year
Relative strength −11%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $30 › 200d $28 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +59 funds added
Insider flow Distributing
Net -$10.0M over 90 days · 100% sells
Short interest Rising
22.75% of float · ▲ +1.2% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
275 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Strong
Revenue growth +33%
Y/Y
EPS growth +82%
Y/Y
Free cash flow $-360.0M
Balance sheet $294.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 76%
annualized · 1-yr
Max drawdown −38%
past year
ATR 5.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Prior guidance period ended · from the 8-K filed Jan 12, 2026
Cash, cash equivalents and marketable securities (estimated as o · as of December 31, 2025 $1.25B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+3% Bullish
Price vs 50-day avg
−3% Neutral
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
60% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $30 › 200d $28 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +59 funds added
Insider flow Distributing
Net -$10.0M over 90 days · 100% sells
Short interest Rising
22.75% of float · ▲ +1.2% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
275 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $16 Now $29 · 60% Range high $38
vs 200-day avg +3% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BEAM
Beam Therapeutics Inc.
this stock
$2.74B +4.9% +33.3% — 22.8%
ONC
BeOne Medicines Ltd.
 $557.05B +24.0% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.88B +21.8% +46.2% 30.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.27B +8.9% +20.8% 20.3 3.3%
MRNA
Moderna, Inc.
 $69.62B +491.3% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
275
% held
106.5%
Net QoQ
+891.7K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
249
View
Short & Settlement
Short Interest Rising
Shares short
23.5M
Days to cover
11.3d
Change
+283.0K sh
View
Short Volume
Short vol %
63%
As of
Aug 19, 2026
Short Total
View
Fails to Deliver
FTD shares
6.4K
Value
$169.9K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
41.5%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$10.0M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$139.7M
Net income (FY)
$-80.0M
EPS diluted
$-0.81
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 4, 2026
This year
12
View
Proposed Sales
Value
$429.3K
Shares
16.7K
Filed
Jul 27, 2026
View
Earnings & Events
Earnings Calls
Last call
Feb 24, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
BEAM +8.8% +9.1% +0.5% +13.9% +4.9%
SPY -0.4% +2.9% +11.6% +3.0% +12.8%
vs SPY +9.3% +6.2% -11.1% +11.0% -7.9%
Key facts CIK 1745999 CUSIP 07373V105 13F (30d) 267 filings 257 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)